Recruiting

Asparaginase

Sponsor:

St. Jude Children's Research Hospital

Code:

NCT07008027

Conditions

Drug Toxicity

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.

Conditions

Drug Toxicity

Study ID

NCT07008027

Start date

Dec, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2031

Anticipated

Primary completion date

Jul, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia
  • Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy
  • Post-INITIALL therapy is:

  • Standard of Care (SOC)/Non Protocol Treatment Plan (NPTP) as per Total therapy or
  • SJALL23T and not scheduled to receive venetoclax

Exclusion Criteria:

  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Non-protocol therapy /standard of care therapy

Participants receiving non -protocol standard if care (SOC) treatment.

SJALL23T (NCT06390319) protocol therapy

Participants receiving protocol therapy on SJALL23T and not receiving investigational drug.

Primary outcome measure

  • Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities during standard of care (SOC) therapy [ Time Frame: Approximately 2½ to 3 years ]
  • Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities SJALL23T therapy [ Time Frame: Approximately 2½ to 3 years ]
  • Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SOC therapy [ Time Frame: Approximately 2½ to 3 years ]
  • Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SJALL23T therapy [ Time Frame: Approximately 2½ to 3 years ]
  • Probabilities of grade 3+ or 4+ toxicities each phase of SOC treatment [ Time Frame: Approximately 2½ to 3 years ]
  • Probabilities of grade 3+ or 4+ toxicities each phase of SJALL23Ttreatment [ Time Frame: Approximately 2½ to 3 years ]

Central Contacts and Locations

Central contacts

Locations

St. Jude Children's Research Hospital

Recruiting

Memphis, Tennessee, United States, 38105

Contacts

Principal Investigator:

Seth E. Karol, MD, MSCI

More Information

Sponsor

St. Jude Children's Research Hospital

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Asparaginase drugs
  • Toxicity
  • Acute lymphoblastic leukemia
  • Acute lymphoblastic lymphoma
  • Mixed phenotype acute leukemia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by St. Jude Children's Research Hospital on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.